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S260 Poster Session IIObjectives: To evaluate parent and physician perspectives and
patterns of EOL care for children after SCT.
Methods: Retrospective, cross-sectional survey of 141 parents of
children who died of cancer, and primarily received care at one of
two tertiary care pediatric institutions (response rate 64%). Chart re-
view provided additional information. Children for whom SCT was
the last cancer therapy (n5 31) were compared with those for whom
it was not (non-SCT, n5 110).
Results: The SCT group included 22/31 (71%) allogeneic and 9/
31 (29%) autologous SCT. The median (IQR) interval between last
cancer treatment and death was 65 (30-127) days (SCT group) and
25 (8-59) days (non-SCT) (p\0.001). SCT children were more
likely to die from toxicity (p\0.001). SCT parents and physicians
recognized no realistic chance for cure (RCC) later than their non-
SCT peers (Table 1) and were more likely to have a primary goal of
cure/life extension at death (parents p\0.001, physicians
p5 0.02). SCT children were more likely to die in the ICU
(p\0.001), with less opportunity for location of death to be
planned (p\0.001) or hospice to be involved (p\0.001). For
SCT children, resuscitation discussions occurred later (p\0.001)
and resulted in fewer DNR orders (p5 0.028). SCT children
were more likely to suffer highly from their last cancer therapy
(p5 0.034), and experienced more physical and psychological
symptoms (p\0.009 and \0.007, respectively). For the 13 SCT
children whose parent and physician recognized no RCC .7
days before death, intubation was less likely (p5 0.05) and resusci-
tation discussion and LOD planning more likely (both p5 0.02).
SCT parents who recognized no RCC$ 7 days before death along
with the physician, were more likely to prepare for EOL and if
their primary goal was to reduce suffering, to achieve this
(p\0.001).
Conclusion: SCT is associated with significant suffering and less
opportunity to recognize and prepare for EOL. Given the highmor-
bidity and mortality associated with SCT and the shorter time-
frames, children and families undergoing SCT may benefit from
ongoing discussions regarding prognosis, goals and opportunities
to maximize quality of life.
Parent and Physician Understanding of Prognosis: Duration of
recognition of no realistic chance for cure*
SCT (n5 31) non-SCT (n5 110) P†Parents 4 (1-822) 83.5 (29-237) \0.001
Physicians 15.5 (2-30) 84 (29-166) \0.001*Reported as median (inter-quartile range) number of days before death.
†P values correspond to logistic regression models adjusting for time
since death.277
ALTERNATE DAY MICAFUNGIN ANTI-FUNGAL PROPHYLAXIS IN PEDIAT-
RIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (HSCT): A PHARMACOKINETIC (PK) STUDY
Mehta, P.A.1, Vinks, A.2, Filipovich, A.1, Bleesing, J.1, Jodele, S.1,
Jordon, M.1, Marsh, R.1, Tarin, R.1, Edwards, S.L.1, Fearing, D.1,
Davies, S.M.1 1Cincinnati Children’s Hospital Medical Center, OH;
2Cincinnati Children’s Hospital Medical Center, OH
Disseminated fungal infection is a major cause of morbidity and
mortality in children undergoing HSCT. Prophylaxis with ampho-
tericin B can be limited by it’s renal toxicity. Oral triazoles are lim-
ited by poor absorption, large inter-individual PK variability and
hepatic toxicity, leading to breakthrough infections. Intravenous mi-
cafungin has a distinct advantage due to its better safety profile spe-
cifically in terms of hepatic and renal toxicity, and lack of drug-drug
interactions with common medications used in the HSCT setting.
We hypothesized that higher dose micafungin (3 mg/kg) every other
day will provide drug exposure similar to standard dose (1 mg/kg)
given daily, and improve patient compliance at reduced administra-tion costs. Both animal and adult patient data support the use of this
approach.
Fifteen children (M/F5 11/4, age #10 y; mean 3.9 y, range
0.6-10 y) with various hematological, metabolic and immune de-
ficiency disorders undergoing HSCT received a single dose of
Micafungin (3 mg/kg) intravenously over 1 hour. Dose selection
was based on published PK data in pediatric patients (Seibel et
al. ntimicrob Agents Chemother, 2005), and exploration of differ-
ent dosing regimens using Monte Carlo PK/PD simulation.
Blood samples were drawn around this dose (pre-dose, at the
end of infusion (1 h), and at 1.5, 2, 4, 6, 10, 24, 36 and 48 h
post dose) and PK analysis was conducted using standard non-
compartmental methods. In addition, we evaluated free AUC/
MIC (minimum inhibitory concentration) and Peak/MIC ratios
as target pharmacodynamic indices.
Micafungin at 3 mg/kg dose was well tolerated in all patients.
Measurable plasma concentrations were present in all cases at
48 hours (Table 1). Half-life and clearance observed were compara-
ble to previous pediatric PK data, with clearance being higher than
adults as expected. Volume of distribution was higher in our patients
compared to published pediatric data, likely due to a larger propor-
tion of very young children in our study cohort (\2 yrs, n5 3; 2-5
yrs, n5 9; 5-10 yrs, n5 3).
Our data show measurable plasma levels at 48 hours after
a single 3 mg/kg dose of Micafungin. After correction for pro-
tein binding, concentrations at the end of the dosing interval
during maintenance treatment will remain well above the MIC
of most common fungal pathogens. This finding suggests that
alternate day Micafungin dosing, as described here, may provide
an attractive alternative for antifungal profylaxis in HSCT
patients.
Table 1. Plasma Micafungin Pharmacokinetic Parameters
Standard
Parameters (unit) Mean Deviation (SD) RangeCmax (mg/L) 12.5 2.7 8.25 – 18.69
Cmin (mg/L at 48 hr) 0.8 0.5 0.27 – 1.99
AUC0-24 (hr*mg/L) 128.5 35.9 79.29 – 229.18
AUC0-48 (hr*mg/L) 164.4 50.7 97.46 – 305.16
AUC0-INF (hr*mg/L) 180.8 62.2 104.18 – 352.87
Cl (ml/hr/kg) 17.7 5.8 7.89 – 29.62
T 1⁄2 (h) 13.0 2.1 9.45 – 16.84
Vss (L/kg) 0.3 0.1 0.22 – 0.48Cmax - peak plasma concentration; Cmin - trough plasma concentra-
tion, AUC0-24 area under the plasma concentration-time curve at
24hrs, AUC0-48 area under the plasma concentration-time curve at
48hrs, AUC0-INF area under the plasma concentration-time curve ex-
trapolated to infinity, Cl total body clearance, T 1⁄2 elimination half-life,
Vss volume of distribution.278
DRUG INTERACTION BETWEEN ORAL CALCINEURIN INHIBITORS (TA-
CROLIMUS AND CYCLOSPORINE A) AND ORAL VORICONAZOLE IN THE
RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION
Mori, T., Kato, J., Aisa, Y., Yamane, A., Ono, Y., Okamoto, S. Keio Uni-
versity School of Medicine, Tokyo, Japan
Although drug interaction between calcineurin inhibitors such as
tacrolimus and cyclosporine A (CsA) and voriconazole has long been
recognized, it has not been systemically evaluated. Based on the
limited data, a uniform dose reduction of calcineurin inhibitors on
initiating voriconazole (1/2 for CsA, 1/3 for tacrolimus) is recom-
mended. To date, the administration route (i.v. or oral) on the
drug interaction has not been the main subject of evaluation and dis-
cussion. In the present study, the drug interaction between calci-
neurin inhibitors and voriconazole were evaluated in recipients of
